Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yandong Shen

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|September 5, 2023
Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBLYandong Shen, Jane A Freeman, Ian Kerridge, et al.
Leukemia & Lymphoma|January 17, 2019
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Suneet Sandhu, et al.
British Journal of Haematology|May 17, 2018
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironmentKyle Crassini, Yandong Shen, William S Stevenson, et al.
Leukemia & Lymphoma|June 19, 2018
Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cellsKyle Crassini, Tahni Pyke, Yandong Shen, et al.
Blood Advances|October 21, 2020
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Narjis Fatima, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemiaNarjis Fatima, Kyle R Crassini, Lauren Thurgood, et al.
Leukemia & Lymphoma|April 7, 2020
Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphomaGrace K Gifford, Andrew J Gifford, Qian Chen, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 10, 2021
Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell linesJuhura G Almazi, Munther Alomari, Larissa Belov, et al.
Acta Orthopaedica|April 4, 2019
Artificial intelligence detection of distal radius fractures: a comparison between the convolutional neural network and professional assessmentsKaifeng Gan, Dingli Xu, Yimu Lin, et al.
Molecular Cancer Research : MCR|July 2, 2013
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancerXiaosong Chen, Meizhong Zhao, Mingang Hao, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|September 5, 2023
Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBLYandong Shen, Jane A Freeman, Ian Kerridge, et al.
Leukemia & Lymphoma|January 17, 2019
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Suneet Sandhu, et al.
British Journal of Haematology|May 17, 2018
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironmentKyle Crassini, Yandong Shen, William S Stevenson, et al.
Leukemia & Lymphoma|June 19, 2018
Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cellsKyle Crassini, Tahni Pyke, Yandong Shen, et al.
Blood Advances|October 21, 2020
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironmentYandong Shen, Kyle Crassini, Narjis Fatima, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemiaNarjis Fatima, Kyle R Crassini, Lauren Thurgood, et al.
Leukemia & Lymphoma|April 7, 2020
Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphomaGrace K Gifford, Andrew J Gifford, Qian Chen, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 10, 2021
Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell linesJuhura G Almazi, Munther Alomari, Larissa Belov, et al.
Acta Orthopaedica|April 4, 2019
Artificial intelligence detection of distal radius fractures: a comparison between the convolutional neural network and professional assessmentsKaifeng Gan, Dingli Xu, Yimu Lin, et al.
Molecular Cancer Research : MCR|July 2, 2013
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancerXiaosong Chen, Meizhong Zhao, Mingang Hao, et al.
Pageof 3